Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.50 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | GLA | P06280 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221025 | 0.76 | ERCC1 (0.52) | ERCC1ERCC4ALDH1A1GLAHPGD | |
| SCHEMBL16244630 | 0.75 | KDM1A (0.33) | ERCC1ERCC4KDM1A | |
| SCHEMBL25044537 | 0.75 | DAO (0.50) | ERCC1ERCC4ALDH1A1HCAR1GAA | |
| SCHEMBL2995837 | 0.75 | PKM (0.54) | ALDH1A1GAAGLAKDM4EHPGD | |
| SCHEMBL14407007 | 0.75 | DAO (0.50) | ALDH1A1GAAGLAKDM4EHPGD | |
| SCHEMBL28174271 | 0.72 | PARP1 (0.33) | ALDH1A1GAAGLAKDM4EHPGD | |
| SCHEMBL23048401 | 0.72 | GRIA1 (0.39) | ALDH1A1GAAGLAKDM4EHPGD | |
| SCHEMBL15829213 | 0.72 | ALDH1A1 (0.39) | ALDH1A1GAAGLAKDM4EHPGD | |
| SCHEMBL19806010 | 0.71 | — | — | |
| SCHEMBL31274939 | 0.71 | NT5E (0.35) | ERCC1ERCC4ALDH1A1GAAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4608821-A1 | PHARMACEUTICAL COMPOUNDS AS PARP7 AND/OR PARP1 INHIBITORS | Duke Street Bio Limited (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-4594314-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | Azkarra Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025119372-A2 | MRGPRX2 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118069-A | MRGPRX2 antagonists and uses | 武汉人福创新药物研发中心有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119968364-A | Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds | 阿兹卡拉疗法公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025045246-A1 | PARP7 INHIBITOR AND USE THEREOF | 重庆华森英诺生物科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119330972-A | PARP7 inhibitor and application thereof | 重庆华森英诺生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240425481-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-2547662-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| WO-2012139775-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| WO-2011113309-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-0984961-B1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| US-6143751-A | Pyridine derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2000-11-07 | — | — | US | disclosed |
| CN-1258296-A | Pyridine derivatives and pharmaceutical compositions containing them | ASTRA PHARMA PROD (GB) | 2000-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | ERCC1 4881/4885ERCC4 4885/4885ALDH1A1 2005/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | ERCC1 3887/4885ERCC4 4120/4885ALDH1A1 1201/4885 |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | ERCC1 106/4885ERCC4 130/4885ALDH1A1 1213/4885 |
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | ERCC1 3438/4885ERCC4 4147/4885ALDH1A1 3412/4885 |
| US-20240425481-A1 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRD3, BRDT, BRD4 | ERCC1 1372/4885ERCC4 603/4885ALDH1A1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.